ClinConnect ClinConnect Logo
Search / Trial NCT05191823

Omega Tots Long Term Follow-up

Launched by SARAH KEIM · Jan 10, 2022

Trial Information

Current as of July 22, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

The overall objective with the present study is to determine the long-term effects of docosahexaenoic acid (DHA) plus arachidonic acid (AA) supplementation on general cognitive ability, language, and executive function, and to examine genetic explanations for treatment effects, through one comprehensive study visit with children and parents from the Omega Tots trial cohort (NCT01576783).

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Previous participation in Omega Tots (NCT01576783).
  • Current age of 8 years, 180 days to 10 years, 180 days.
  • Exclusion Criteria:
  • Child in custody of children's services for their window of eligibility

About Sarah Keim

Sarah Keim is a prominent clinical trial sponsor known for her commitment to advancing pediatric health research. With a robust background in epidemiology and a focus on improving health outcomes for children, she leads innovative studies that address critical gaps in understanding childhood diseases and treatments. Her collaborative approach fosters partnerships with academic institutions, healthcare organizations, and regulatory bodies, ensuring that research is conducted with the highest standards of ethics and scientific rigor. Through her leadership, Sarah Keim aims to contribute valuable insights that inform clinical practice and policy, ultimately enhancing the quality of care for pediatric populations.

Locations

Columbus, Ohio, United States

Patients applied

0 patients applied

Trial Officials

Sarah Keim, PhD

Principal Investigator

Nationwide Children's Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials